While industrial payers have been engaged with the shift to biosimilars, all of them have their very own most popular biosimilar, which makes it difficult for practices, defined Lalan Wilfong, MD, vice chairman of payer relations & observe transformation at The US Oncology Network.
While industrial payers have been engaged with the shift to biosimilars, all of them have their very own most popular biosimilar, which makes it difficult for practices, defined Lalan Wilfong, MD, vice chairman of Payer Relations & Practice Transformation at The US Oncology Network.
Transcript
What has been your expertise with industrial payer contracts on the use of biosimilars? Are they encouraging biosimilar use?
In our expertise, industrial payers are wanting to transfer to biosimilars. Many of them—as a result of of what they do and having to be held accountable to their employers and different people who find themselves shopping for providers from the insurers—they do need to make the most of providers that decrease the price of care. We have seen a shift to biosimilars for our industrial payers.
I’ll say the problem with them is that every one of them need to decide a winner that they like, which makes it extraordinarily difficult for a observe to have to shift gears for each affected person that walks in the door and use the insurer’s “preferred biosimilar” versvsus simply utilizing biosimilars. And we at all times advocate for doctor selection and that if we’re going to use biosimilars, allow us to give you the option to decide the biosimilar that we wish to use so it is a lot simpler on a observe to give you the option to handle their affected person inhabitants, relatively than having to change gears with each single affected person that walks in the door.
